Bausch Health Companies Inc (NYSE:BHC)

28.49
Delayed Data
As of Oct 15
 +0.06 / +0.21%
Today’s Change
16.08
Today|||52-Week Range
34.80
+36.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$10.0B

Company Description

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Contact Information

Bausch Health Cos., Inc.
2150 St. Elzéar Boulevard West
Laval Qubec H7L 4A8
P:(514) 744-6792
Investor Relations:
(514) 856-3855

Employees

Shareholders

Other institutional56.60%
Mutual fund holders16.79%
Individual stakeholders13.11%

Top Executives

Joseph C. PapaChairman & Chief Executive Officer
Thomas J. AppioPresident & Co-Head-Bausch Lomb International
Sam EldessoukyCFO, Chief Accounting Officer, SVP & Controller
Tage RamakrishnaChief Medical Officer, President-R&D
Christina M. AckermannExecutive Vice President & General Counsel